The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | High treatment attrition in newly diagnosed multiple myeloma patients
Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses a study investigating the number of newly diagnosed, non-transplanted multiple myeloma patients who are receiving a line of therapy that can progress to a subsequent line of therapy. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Fonseca describes the high level of treatment attrition measured in the study, with a 50% drop in the number of patients able to progress in their therapy.
